CureVac nabs a top Novartis scientist for CSO slot as mRNA vaccines seize the spotlight
One of the key players in the race to develop a new mRNA vaccine to fight Covid-19 has reshuffled the top spots in the executive suite. And they’re bringing in a Novartis vet out of Harvard to spearhead their work on mRNA.
CureVac, which just filed for an IPO that’s still taking shape, has formally handed Franz-Werner Haas the CEO title, after giving it to him on an interim basis. And the still rather stealthy German biotech largely owned by billionaire Dietmar Hopp has recruited Igor Splawski as its chief scientific officer.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 98,000+ biopharma pros reading Endpoints daily — and it's free.